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In this study, we define a new role for lipocalin prostaglandin
D synthase (L-PGDS) in the control of metabolic fuel utilization
by brown adipose tissue (BAT). We demonstrate that L-PGDS
expression in BAT is positively correlated with BAT activity,
upregulated by peroxisome proliferator–activated receptor
g coactivator 1a or 1b and repressed by receptor-interacting pro-
tein 140. Under cold-acclimated conditions, mice lacking L-PGDS
had elevated reliance on carbohydrate to provide fuel for ther-
mogenesis and had increased expression of genes regulating gly-
colysis and de novo lipogenesis in BAT. These transcriptional
differences were associated with increased lipid content in BAT
and a BAT lipid composition enriched with de novo synthesized
lipids. Consistent with the concept that lack of L-PGDS increases
glucose utilization, mice lacking L-PGDS had improved glucose
tolerance after high-fat feeding. The improved glucose tolerance
appeared to be independent of changes in insulin sensitivity, as
insulin levels during the glucose tolerance test and insulin, leptin,
and adiponectin levels were unchanged. Moreover, L-PGDS knock-
out mice exhibited increased expression of genes involved in
thermogenesis and increased norepinephrine-stimulated glu-
cose uptake to BAT, suggesting that sympathetically medi-
ated changes in glucose uptake may have improved glucose
tolerance. Taken together, these results suggest that L-PGDS
plays an important role in the regulation of glucose utilization
in vivo. Diabetes 61:3139–3147, 2012
O
besity is a chronic illness that is associated with
multiple secondary diseases, including diabetes
and cardiovascular disease. Although many
ideas have been put forward to explain mech-
anistically how obesity leads to metabolic complications,
this still remains an area of considerable controversy. We
and others have suggested that alterations in how lipids
are stored and handled may link obesity to metabolic
complications through defects in adipose tissue expansion
and functional capacity and the process of lipotoxicity
(1,2).
An important aspect of appropriate lipid handling is the
ability of tissues to switch between carbohydrate and lipid
as their major metabolic substrates. Under normal physi-
ological conditions, humans switch from using high levels
of carbohydrate during the postprandial state to pre-
dominantly utilizing stored lipids during the fasted state.
The process of switching from fed to fasted states requires
adipose tissue to play an important role in lipid buffer-
ing. During the fed state, net lipid flux into adipose tis-
sue increases, whereas in the fasted state net lipid efflux
predominates (3). Under pathological conditions where
adipose tissue becomes insulin resistant, however, the
appropriate fluxes into and out of adipose tissue are
blunted (4–6).
The process of being able to switch between using
metabolic substrates is termed metabolic flexibility and
can be measured by assessing the change in respiratory
quotient between fed and fasted states. A reduction in
metabolic flexibility has been suggested to be a primary
defect leading to insulin resistance. When fed a high-fat
diet for 3 days, subjects with a family history of type 2
diabetes showed a lower change in respiratory quotient
between fasted and fed states than did subjects without
a family history of type 2 diabetes (7). The fact that
impairments in metabolic substrate utilization may be
a primary cause of insulin resistance suggests the possi-
bility of a direct regulatory mechanism controlling this
process; however, what form this mechanism takes is
poorly understood.
In addition to the known roles for white adipose tissue
(WAT) depots in metabolic health, interest in the role of
brown adipose tissue (BAT) in adult humans has recently
experienced a resurgence through studies with fluo-
rodeoxyglucose positron emission tomography (8–13).
BAT has been demonstrated, at least in rodents, to have
a very high capacity for both lipid and glucose uptake and
oxidation. In small mammals, such as mice, BAT may be
responsible for the oxidation of as much as 90% of the total
daily fuel intake. In addition to its high rate of lipid and
glucose oxidation, BAT also has very high rates of de novo
lipogenesis, suggested to account for as much as 40% of all
de novo lipogenesis in a cold-exposed rats (14). Given
BAT’s very high metabolic rate, its high levels of lipid and
glucose oxidation, and its substantial lipid synthesis, elu-
cidation of how fuel utilization is regulated within BAT is
an important question, particularly if it is ever to be used
efficiently as a therapy to treat human metabolic disease.
In this study we investigate the role of lipocalin prosta-
glandin D synthase (L-PGDS) in the regulation of carbo-
hydrate and lipid utilization by BAT.
L-PGDS has at least two known functions. It is capable
of synthesizing D-series prostaglandins, and it also can
act as a carrier of lipophilic molecules (15). It has been
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reported to have a protective role in the development of
atherosclerosis (16). Reports regarding the role of L-PGDS
in insulin sensitivity, however, are unclear. One report
stated that lack of L-PGDS causes glucose intolerance,
whereas a second report demonstrated that mice lack-
ing L-PGDS had greater adiposity but unaltered glucose
tolerance—suggesting that L-PGDS knockout (KO) mice
may be disproportionately glucose tolerant for their de-
gree of adiposity (16,17).
In this study we demonstrated that L-PGDS is highly
regulated in BAT. To investigate a putative role for L-PGDS
in BAT function, L-PGDS KO mice were cold acclimated.
Cold acclimation causes a substantial increase in whole-
organism metabolic rate and demands large alterations in
carbohydrate and lipid metabolism, particularly in BAT.
Mice lacking L-PGDS had lower basal metabolic rates,
although they were still able to achieve the same maximal
thermogenic capacity as wild-type mice. Crucially, L-PGDS
KO mice had reduced lipid and increased carbohydrate
utilization, appearing to meet increased demand for oxida-
tive capacity from carbohydrate, either directly or by de
novo synthesis of lipids and their subsequent oxidation,
rather than from utilization of dietary lipids. Consistent with
the concept that a lack of L-PGDS increases net glucose
utilization, we showed that mice lacking L-PGDS had im-
proved glucose tolerance when fed a high-fat diet. Overall,
we have defined a role for L-PGDS in the control of fuel
utilization by BAT.
RESEARCH DESIGN AND METHODS
Generation of mice. Mice heterozygous for a disruption in exons II–V in the
L-PGDS gene were crossed to produce L-PGDS KO mice and wild-type
controls (18,19). KO mice for the gene for peroxisome proliferator–activated
receptor g coactivator PGC1b were generated as previously described (20).
KO mice for the RIP140 were generated as previously described (21).
Animal care and diets.Mice were housed at a density of four animals per cage
in a temperature-controlled room (20–22°C) with 12-h light/dark cycles. All
animal protocols used in this study were approved by the U.K. Home Office and
the University of Cambridge. Animals were fed a normal chow diet (D12450B;
Research Diets) or a high-fat diet; either 45% or 60% calories-from-fat diets
(D12451, D12492; Research Diets). For studies of cold acclimation, animals
were housed as described previously (22). These experiments were approved
by the North Stockholm Animal Ethics Committee.
Cell lines and plasmids. The brown fat cell line IMBAT-1 was generated (23)
and differentiated, as described previously (24,25). The RIPKO-1 cell line was
generated by continuous culture of Rip140-null mouse embryonic fibroblasts,
and differentiation of the cells was performed as previously described (26).
Differentiated IMBAT-1 or RIPKO-1 adipocytes were infected with adenovirus
vectors expressing Rip140, PGC1a, or green fluorescent protein gene (26).
Equal levels of infection were confirmed by fluorescence microscopy for the
coexpressed green fluorescent protein.
Eicosanoid extraction and quantification. Eicosanoids were extracted
from 50 to 100 mg of BAT by solid-phase extraction and quantified by liquid
chromatography-mass spectrometry as described previously (27).
Hepatic glycogen assay. Glycogen levels were determined by the anthrone
method (28).
Hepatic triglyceride analysis. Lipids were extracted from 100 mg of ho-
mogenized liver by heating to 85°C in 1 mL of 5% NP-40 in water. Triglyceride
(TG) levels in extracts were assessed by enzymatic assay (Biovision)
according to manufacturer instructions.
Blood biochemistry and body composition analysis. Enzymatic assay kits
were used for determination of plasma free fatty acids (Roche) and TGs (Sigma-
Aldrich, St. Louis, MO). Enzyme-linked immunosorbent assay kits were used for
measurements of leptin (R & D Systems), insulin (DRG; Diagnostics In-
ternational Limited), and adiponectin (B-Bridge International) according to
manufacturer instructions. A Minispec LF TD-NMR (Brucker Optics) was used
to measure body composition.
Fatty acid methyl ester analysis. The lipid extract was derivatized by acid-
catalyzed esterification (29) with 10% BF3 in methanol (Sigma-Aldrich, Gilling-
ham, U.K.), and the esterification was performed at 80°C for 90 min. Once cool,
water and hexane were added, and the aqueous layer was discarded. The organic
layer was dried and then reconstituted in hexane for gas chromatography–flame
ionization detection analysis (GC-FID) with a Trace GC Ultra (ThermoScientific).
Derivatized organic samples were injected onto a 30-m 3 0.25-mm 70% cyano-
propyl polysilphenylene-siloxane 0.25 mm TR-FAME stationary-phase column
(ThermoScientific). The initial column temperature was 55°C for 2 min, in-
creased by 15°C/minute to 150°C and then increased at a rate of 4°C/minute to
230°C, where it was held for 30 s.
Norepinephrine-induced thermogenesis. Norepinephrine-induced thermo-
genesis was measured through oxygen consumption, as determined by the
INCA system (Somedic, Hörby, Sweden) as described previously (30).
Glucose and pyruvate tolerance tests. Mice were fasted overnight from
4 P.M. until 9 A.M. the next day. Mice were injected intraperitoneally with
either glucose (1 g/kg) or pyruvate (1.3 g/kg), and blood glucose levels were
measured with a One-Touch Ultra glucose meter (Lifescan, Milpitas, CA). Blood
samples for insulin measurement were collected with glass capillary tubes.
Histology. Samples for histology were placed in 10% buffered formalin
overnight before transfer to 70% ethanol and later embedding in paraffin.
Multiple sections were stained with hematoxylin and eosin for morphological
analysis. Percentages of lipid content and adipocyte area were determined by
morphometric analysis. The average lipid area in BAT and cell size in WAT per
mouse were calculated from at least 3 separate sections. Analysis was carried
out with CELL^P analysis software (Olympus, Southend-on-Sea, U.K.).
Quantitative real-time PCR. Total RNA was isolated from cells and BAT
fractions with RNeasy Mini columns (Qiagen). RNA was isolated from
ground tissues with STAT-60 reagent (TEL-TEST), followed by chloroform
extraction and isopropanol precipitation. The cDNA was generated with
M-MLV reverse transcriptase (Promega) according to the manufacturer
instructions. Real-time PCR was carried out with TaqMan primers and probes
or SYBR green reagent (Applied Biosystems) with an ABI Prism 7900 se-
quence detection system (Applied Biosystems) according to the manufac-
turer instructions. Data were normalized to 18s rRNA. Primer sequences are
available on request.
Norepinephrine-stimulated glucose uptake. Mice were fasted overnight.
Mice were subsequently anesthetized with 90 mg/kg sodium pentobarbital.
After 10–15 min to allow full sedation, the tail vein was cannulated. A basal
glucose sample was taken, and mice were injected with 0.2 MBq of 2-[14C]-
deoxyglucose (2-[14C]-DG) (Perkin Elmer) and 1 mg/kg norepinephrine bis-
tartrate. Glucose was measured at 10, 20, and 30 min with an AlphaTRAK
(Abbott) glucose meter calibrated for rodents. Blood samples (30 mL) were
collected at 10 and 20 min from the tail vein for measurement of serum DPM.
At 30 min, animals were exsanguinated by cardiac puncture. Tissues were
collected and frozen on dry ice. The 2-[14C]-DG uptake into tissues was
quantified with the BaOH2/ZnSO4 precipitation method as described pre-
viously (31).
Statistics. Results were expressed as mean 6 SEM. Statistical analysis was
performed with SPSS 17.0 (IBM, Armonk, NY). Pairwise comparisons were
carried out by Student t test. For data with more than two groups, ANOVA was
carried out, followed by Tukey post hoc test. For groups with multiple groups
and conditions, two-way ANOVA was carried out.
RESULTS
Regulation of L-PGDS in BAT from states of altered
thermogenesis. Two paradigms of BAT activation were
investigated: 1) cold exposure and 2) high-fat feeding.
L-PGDS expression was physiologically upregulated in the
BAT of mice after either cold acclimation (4°C) or high-fat
feeding (45% calories from fat) relative to chow-fed mice
housed at room temperature (22°C) (Fig. 1A). Conversely,
mice housed at thermoneutrality (30°C) for 3 weeks had de-
creased L-PGDS expression relative to room temperature–
housed control mice (Fig. 1B). To identify putative
transcriptional regulators of L-PGDS, we focused on key
factors implicated in BAT activation. Both PGC1a and
PGC1b have been shown to be positive regulators of BAT
function, whereas RIP140 is a negative regulator of BAT
function (20,32). L-PGDS was found to be down regulated
in mice lacking PGC1a (Fig. 1C) or PGC1b (Fig. 1E) but
upregulated in mice lacking Rip140 (Fig. 1D). Finally,
and consistent with a metabolic role for L-PGDS, L-PGDS
was found to be predominantly expressed in mature
brown adipocytes rather than the stromal vascular fraction
(Fig. 1F).
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Reciprocal regulation of L-PGDS by PGCs and RIP140
in vitro. To investigate further the reciprocal regulation of
L-PGDS by PGCs and RIP140, cellular models were used. In
a BAT cell line, ectopic overexpression of PGC1a caused
an increase in endogenous L-PGDS mRNA levels (Fig. 2A).
Conversely, increasing expression of Rip140 led to a de-
crease in L-PGDS expression levels (Fig. 2B). Finally, with
Rip140 KO embryonic fibroblasts, we showed that titrating
RIP140 back into these cells resulted in a proportional
decrease in L-PGDS expression (Fig. 2C).
L-PGDS regulates fuel utilization in vivo. To test
whether L-PGDS was required for appropriate BAT func-
tion, L-PGDS KO mice were sequentially acclimated to
either 4°C or thermoneutrality (30°C) for a period of 3
weeks. At each temperature, both basal and maximal
thermogenic capacity were measured. L-PGDS KO mice
exhibited no alterations in their norepinephrine-stimulated
(maximal) rates of oxygen consumption; however,
L-PGDS KO mice did exhibit a small reduction in their
basal energy expenditure after housing at 4°C (Fig. 3A).
Although changes in energy expenditure in L-PGDS
KO mice were modest, there was a large alteration in
their respiratory exchange ratio (RER) after norepi-
nephrine stimulation at both 4°C and 30°C. Under
unnstimulated conditions, L-PGDS KO mice only exhibi-
ted an increase in RER when they had been previously
acclimated to 4°C (Fig. 3B). The elevated RER of the
L-PGDS KO mice relative to wild-type littermates sug-
gests that L-PGDS KO mice met their increased demand
for energy at 4°C by utilizing more carbohydrate than did
wild-type mice.
Cold-acclimated L-PGDS KO mice exhibit altered
lipid metabolism in BAT and liver. After cold acclima-
tion, L-PGDS KO mice had increased lipid content in BAT
relative to wild-type mice (Fig. 3C). Lipids were extracted
from wild-type and L-PGDS KO mice that had been accli-
mated to 4°C for 3 weeks and were analyzed by GC-FID.
The lipid profile of the L-PGDS KO mice, when compared
with wild-type controls, demonstrated a reduction in the
proportion of dietary-derived essential fatty acids (C18:2
and C18:3), and an increase in the proportion of oleate
(C18:1), which can be either derived from the diet or
synthesized de novo (Fig. 3D). In accordance with ele-
vated de novo lipogenesis, BAT from L-PGDS KO mice
also had increased expression of the lipogenic genes for
fatty acid synthase (FAS), stearoyl coenzyme A desaturase
1 (Scd1), and elongase 6 (Elovl6) (Fig. 4A). When com-
pared with wild-type mice, L-PGDS KO mice had increased
mRNA levels in BAT of the glucose transporter gene Glut4,
a-enolase, and phosphofructokinase, genes involved in
glucose uptake and glycolysis (Fig. 4B). Remarkably, the
gene expression changes in both carbohydrate metabolism
and fatty acid synthesis were highly specific. Although
there was a small increase in UCP1 expression in BAT,
FIG. 1. A: L-PGDS mRNA is induced in active BAT, as shown in com-
parison of mice housed at 22°C fed a chow diet (CTRL); mice housed at
22°C fed a 45% calories-from-fat diet from weaning (HFD); and mice
housed at 4°C for 3 weeks before tissue collection fed a chow diet (CE).
All groups consisted of male mice n > 7 per group, C57Bl/6 background,
4 months old. B: L-PGDS mRNA levels are reduced in inactive BAT, as
shown in comparison of mice housed for 3 weeks before tissue collec-
tion at either 22°C or 30°C fed a chow diet. Both groups consisted of
female mice, n > 7 per group, mixed sv129/Bl6 background, 4 months
old. C: L-PGDS mRNA levels in BAT are significantly lower in PGC1a
KO mice compared with littermate controls (WT). Both groups con-
sisted of male mice, n = 8 per group, C57Bl/6 background, 12 months
old. D: Rip140 KO mice (RIP140) have significantly increased mRNA
levels of L-PGDS in BAT relative WT. Both groups consisted of male
mice, n = 4 per group, C57Bl/6 background, 4 months old. E: L-PGDS
mRNA levels are significantly lower in PGC1b KO mice (PGC1b) com-
pared with WT at both 30°C and 4°C. Both groups consisted of male
mice, n = 5 per group, C57Bl/6 background, 4 months old. F: L-PGDS
mRNA is expressed predominantly in mature adipocytes (Ad) relative
to stromal vascular fraction (SVF). Both groups consisted of male mice,
n = 8 per group, C57Bl/6 background, 4 months of age. Asterisks in-
dicate P < 0.05.
FIG. 2. A: L-PGDS mRNA levels are increased in an immortalized brown
adipocyte cell line transfected with PGC1a. B: L-PGDS mRNA levels
are suppressed in an immortalized brown adipocyte cell line trans-
fected with Rip40 (RIP140). C: L-PGDS mRNA levels are suppressed by
RIP140 reexpression in mouse embryonic fibroblasts derived from
Rip140 KO mice in a dose-dependent manner. For all, n = 3 independent
experiments.
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there were no significant changes observed in genes reg-
ulating brown adipocyte function, fatty acid oxidation,
lipid uptake, or brown adipocyte differentiation (Fig. 4C
and Supplementary Fig. 1). Taken together, these data
suggest that L-PGDS ablation results in active BAT that
preferentially utilizes glucose, either directly as a substrate
for thermogenesis or for de novo lipogenesis and sub-
sequent b-oxidation.
FIG. 3. A: L-PGDS KO mice have no difference in maximal norepinephrine-stimulated (NE) oxygen consumption after acclimation to either 4°C or
30°C but demonstrate a reduction in basal energy expenditure (EE) after acclimation to 4°C. Maximal oxygen consumption was analyzed by
injecting anesthetized mice with norepinephrine. All measurements were conducted at 33°C regardless of previous acclimation temperature. Solid
triangles, WT mice acclimated to 4°C; open triangles, KO mice acclimated to 4°C; solid circles, WT mice acclimated to 30°C; open circles, KO mice
acclimated to 30°C. B: Under basal conditions, L-PGDS KOmice (L-PGDS KO) have an increased RER compared with wild-type controls (WT) after
housing at 4°C but not after housing at 30°C. After stimulation with norepinephrine, L-PGDS KO mice have an increased RER compared with wild-
type mice regardless of previous housing. C: Representative histological sections of BAT from WT and L-PGDS KO mice housed at 4°C (left) and
morphometric analysis of histology quantified for lipid droplet area per brown adipocyte (right) in L-PGDS KO mice (white bars) and WT controls
(black bars). Both groups consisted of male mice, n> 5 per group, C57Bl/6, 7 months old. D: Analysis of fatty acid methyl esters by GC-FID analysis
shows an increased level of de novo synthesized lipids and reduced levels of dietary essential fatty acids in BAT of L-PGDS KO mice relative to WT
mice. Both groups consisted of male mice, n = 8 per group, C57Bl/6 background, 7 months old. *P < 0.05. (A high-quality digital representation of
this figure is available in the online issue.)
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Similar to the results observed in BAT, L-PGDS KO mice
had increased levels of FAS, Elovl6, and Scd1 mRNA ex-
pression in liver when compared with wild-type mice (Fig.
4D–E). Despite these changes, no increase in hepatic TG
level was detected (Supplementary Fig. 2A). Further to the
changes in de novo lipogenesis, L-PGDS KO mice also
exhibited a reduction in expression of the key gluconeo-
genic enzyme PEPCK (Fig. 4D), although no alterations in
the glycogen biosynthetic program or glycogen levels were
detected (Supplementary Fig. 2B–C). The change in PEPCK
suggests that in the liver, products of the citric acid cycle
were not driven toward production of glucose but instead
were channeled to de novo lipogenesis. This hypothesis
was also supported by the lower plasma glucose of cold-
acclimated L-PGDS KO mice (Table 1) and by a small but
significant reduction in glucose levels in response to a py-
ruvate tolerance test (Supplementary Fig. 2D).
L-PGDS–dependent alterations in lipid metabolism
are organ specific. The major sites of de novo lipogene-
sis in cold-acclimated mice are BAT and liver (14). Con-
sistent with L-PGDS acting principally to regulate fuel
availability to and utilization by thermogenic tissues,
comparatively few changes in gene expression were found
in muscle (Supplementary Fig. 1B–D), epididymal WAT, or
subcutaneous WAT (Supplementary Fig. 3). Overall, under
conditions of cold exposure, loss of L-PGDS appeared al-
most exclusively to affect BAT depots and liver, which in
the cold acts as an important supplier of de novo synthe-
sized lipids for oxidation by BAT.
L-PGDS ablation increases glucose tolerance. Given
that our data had indicated that loss of L-PGDS in cold-
acclimated animals appeared to increase glucose utiliza-
tion to meet energy demands, we next investigated
whether a lack of L-PGDS could affect lipid and carbo-
hydrate metabolism under standard laboratory conditions
(24°C housing). In animals fed a high-fat diet, lack of
L-PGDS caused a significant improvement in glucose tol-
erance (Fig. 5A). Surprisingly, this effect was observed
despite apparently similar degrees of insulin resistance
induced by high-fat diet in WT and L-PGDS KO mice, as
indicated by markers of insulin sensitivity including serum
insulin levels during the glucose tolerance test (Fig. 5B and
Supplementary Fig. 4G); adiposity (Fig. 5C); adipocyte size
(Supplementary Fig. 4A); markers of adipogenesis in BAT,
FIG. 4. Gene expression analysis by real-time PCR from BAT (A–C) and liver (D and E) of L-PGDS KO mice and controls (WT). In BAT, genes
examined are involved in fatty acid synthesis (A), glucose metabolism (B), and uncoupling proteins and markers of thermogenesis (C). In liver,
genes examined are involved in glucose and fatty acid metabolism (D) and fatty acid elongation and desaturation (E). Both groups consist of male
mice, n > 5 per group, C57Bl/6 background, 7 months old, acclimated to 5°C for 3 weeks. *P < 0.05.
S. VIRTUE AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, DECEMBER 2012 3143
subcutaneous WAT, and epididymal WAT (Supplementary
Fig. 4B–D), tissue weights (Supplementary Fig. 4E–F); and
fasted insulin, adiponectin, and leptin levels (Fig. 5E).
Tissue markers of insulin sensitivity were also unchanged
between wild-type and L-PGDS KO mice (Supplementary
Fig. 5). Consistent with increased glucose utilization, mice
lacking L-PGDS had lower fasting glucose levels (Fig. 5D).
Because the changes in glucose tolerance and fasting
glucose did not seem to be associated with markers of
improved insulin sensitivity, we investigated whether there
were any changes in other processes that mediate glucose
uptake. In BAT norepinephrine has been shown to pro-
mote glucose uptake independently of insulin (33). Con-
sistent with increased sympathetic tone or sensitivity to
sympathetic tone, mice lacking L-PGDS had elevated
thermogenic markers in BAT, and the constitutive glucose
transporter gene Glut1 was also upregulated (Fig. 5F). To
test whether response to sympathetic tone in terms of
plasma glucose levels could be modulated by L-PGDS, we
injected wild-type and L-PGDS KO mice with norepineph-
rine (1 mg/kg). As expected norepinephrine increased se-
rum glucose levels as a result of its effects on hepatic
glucose production (34,35); however, in L-PGDS KO mice
the increase in plasma glucose levels was blunted relative to
that in wild-type animals (Fig. 5G). To determine whether
this was due to changes in glucose uptake as opposed to
hepatic glucose uptake, we subsequently included 2-[14C]-
DG as a tracer to measure tissue-specific glucose uptake.
We detected elevated uptake of glucose into BAT in re-
sponse to norepinephrine, with no changes in muscle and
a tendency (P = 0.059) toward increased glucose disposal
into WAT. Although hepatic glucose production could not
be directly assessed in the same assay, the elevated accu-
mulation of 2-deoxy-D-glucose in liver in L-PGDS KO mice
was suggestive of decreased glucose output, because
2-deoxy-D-glucose accumulates in liver by mass action
(through Glut2) but can be actively exported.
Loss of L-PGDS does not affect prostaglandin D2
levels in BAT. Finally, to try to identify a mechanism
for L-PGDS in the regulation of fuel utilization, we mea-
sured prostaglandin D2 and E2 in BAT from cold accli-
mated wild-type and L-PGDS KO mice (Fig. 5I). We
detected no differences in prostaglandin levels, suggesting
that L-PGDS may act as a lipocalin.
DISCUSSION
In this study, we demonstrated that L-PGDS contributes to
the balance between carbohydrate and lipid utilization in
vivo. We also demonstrated that the physiological levels
of L-PGDS mRNA in BAT are strongly and positively cor-
related with activation of BAT metabolism. In vivo char-
acterization of cold-exposed mice lacking L-PGDS
demonstrated that lack of L-PGDS resulted in a modest
impairment in metabolic rate but a substantial increase in
RER. These changes in metabolic rate and RER suggested
that the principal role of L-PGDS was to control the type of
fuel utilized by BAT, rather than the maximal thermogenic
capacity.
The first evidence for a role for L-PGDS in BAT metab-
olism came from its dynamic regulation in response to both
physiological and genetic manipulations which affect BAT
function. L-PGDS mRNA was upregulated in states of ele-
vated BAT function, including cold acclimation and high-fat
feeding, as well as in the Rip140 KO mouse model, which
has substantially increased metabolic rate with elevated
markers of brown adipocyte genes within WAT (32). Con-
versely, L-PGDS mRNA was downregulated by thermo-
neutral housing and in mouse models with reduced BAT
function, including PGC1a and PGC1b KO mice. Notably,
both Rip140 KO and PGC1b KO mice have RER values that
inversely correlate with their L-PGDS levels (20,36), con-
sistent with the elevated RER seen in L-PGDS KO mice.
Although differences in metabolic rate observed between
L-PGDS KOmice and wild-type controls were modest, there
were much more substantial changes in RER. An elevated
RER would usually be considered a marker of increased
carbohydrate utilization and decreased lipid utilization by
an organism; however, conversion of carbohydrate to lipid
and its subsequent oxidation has the same RER as oxidizing
carbohydrate itself, suggesting that either increased direct
metabolism of carbohydrate or increased de novo lipogen-
esis followed by fatty acid oxidation could explain the
differences in RER between wild-type and KO mice. In
agreement with this, molecular analysis of BAT from
L-PGDS KO mice demonstrated an increase in the pro-
portion of de novo synthesized lipid located within BAT,
as well as increased expression of glycolytic and de novo
lipogenic enzymes, when compared with wild-type controls.
Under conditions of cold acclimation, the principal sites of
de novo lipogenesis are BAT and liver (14). Similarly to
BAT, the livers of L-PGDS KO mice also exhibited a gene
expression profile consistent with converting carbohydrate
to lipid but did not exhibit any increase in hepatic TG levels,
suggesting that any increased TG synthesis was potentially
being exported. The molecular prolipogenic changes in liver
and BAT were supported by lower serum glucose levels.
Overall, these data suggest that under conditions of 4°C
housing, L-PGDS is required for appropriate utilization of
dietary lipids. In the absence of L-PGDS, mice were still able
to meet the thermogenic demands of cold exposure; how-
ever, this appeared to be at the expense of a substantial
increase in carbohydrate utilization.
In addition to cold exposure, high-fat feeding has been
shown to promote BAT activation. After feeding with
a very high-fat diet (60% calories from fat), L-PGDS KO
mice had improved glucose tolerance relative to wild-type
mice. Although euglycemic-hyperinsulinemic clamp data
would be needed to formally confirm an absence of
alterations in insulin sensitivity, there were no molecular
markers of insulin resistance that differed between WT
and L-PGDS KO mice, suggesting that the improved glu-
cose tolerance of the L-PGDS KO mice could be driven by
mechanisms not insulin dependent. Consistent with this
concept, the thermogenic program in BAT and the
TABLE 1
Serum biochemistry of WT and L-PGDS KO mice after cold
acclimation
Wild-type L-PGDS KO P value
Insulin (mg/L) 1.69 6 0.36 1.51 6 0.32 0.736
Glucose (mmol/L) 16.94 6 1.67 13.21 6 0.45 0.045
FFA (mmol/L) 555 6 109 572.6 6 31.4 0.876
TG (mmol/L) 1.54 6 0.27 1.7 6 0.128 0.593
Cholesterol (mmol/L) 3.14 6 0.39 2.866 6 0.088 0.481
HDL (mmol/L) 1.92 6 0.15 1.818 6 0.053 0.518
Adiponectin (ng/mL) 18,889 6 1911 17,885 6 646 0.611
Leptin (pg/mL) 6,642 6 1933 5,191 6 711 0.473
Data are mean 6 SEM for male mice, n . 5 per group, C57/Bl6
background, 7 months old. Bold type indicates significant differences
between groups. FFA, free fatty acid.
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FIG. 5. A: Glucose levels during an intraperitoneal glucose tolerance test in wild-type control (WT) mice fed chow (black circles), L-PGDS KOmice
fed chow (white circles), WT mice fed a high-fat diet (black squares), and L-PGDS KO mice fed a high-fat diet. B–I: Area under the curve for
insulin levels during glucose tolerance test (B); body weight (BW), fat mass (FM), and lean mass (LM) (C); fasting blood glucose levels (D);
fasting serum hormone levels (E); gene expressions in intrascapular BAT (F); glucose levels in response to subcutaneous injection of norepi-
nephrine (1 mg/kg) (G); tissue-specific glucose uptake in response to subcutaneous injection of norepinephrine (1 mg/kg) (H); and prostaglandin
levels from BAT of cold-acclimated WT and L-PGDS KO mice (I). All animals were 7-month-old C57Bl/6 males, fed either chow or 60% calories-
from-fat diet (HFD), n = 8 per group, fasted animals (except in H and I), n = 7 per group. a, P < 0.05 for diet; b, P < 0.05 for genotype; c, P < 0.05
for genotype and diet interaction. *P < 0.05.
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constitutive glucose transporter Glut1 were upregulated in
mice lacking L-PGDS. To test the concept that the sym-
pathetic nervous system could regulate glucose levels in
L-PGDS KO mice, we injected mice lacking L-PGDS with
norepinephrine in combination with 2-[14C]DG. Mice
lacking L-PGDS exhibited a 60% increase in glucose dis-
posal to BAT relative to wild-type controls, supporting the
concept of sympathetically mediated glucose uptake into
BAT being elevated in the absence of L-PGDS. BAT
exhibits very high rates of glucose uptake in response to
either norepinephrine or insulin, and although the exact
contribution of glucose as a substrate for thermogenesis
remains debatable, it seems likely that it does contribute
significantly (37). Several publications have demonstrated
sympathetic control of glucose uptake into BAT (38–42)
and that this uptake is dependent on UCP1 (39). Insulin
stimulated uptake of glucose to BAT is not dependent on it
being thermogenically functional (40); however, cold ex-
posure does increase the rate of glucose disposal into BAT
in response to insulin (42). Overall, these results suggest
that BAT can have a major impact on systemic glucose
levels and, importantly, that it can do so independent of
the actions of insulin.
The finding that L-PGDS can mediate fuel provision to
BAT is a potentially important one given the renewed ex-
citement in the potential of BAT to treat metabolic disease
after its rediscovery in adult humans (8,12,43). Although
much research into BAT has focused on its recruitment
and molecular activation, relatively less research has gone
into the supply of nutrients to BAT. Recent articles re-
garding angiogenesis in BAT (44) and the control of lipid
uptake into BAT (45) have helped to further our un-
derstanding of fuel supply to BAT; however, if BAT is ever
to be used to treat human obesity, then it must be both
fully activated and appropriately supplied with nutrients.
The ability of L-PGDS to control in part the balance of lipid
and carbohydrate utilization by BAT highlights another
potential layer of regulation of BAT activity.
To try to address in part how L-PGDS may affect BAT
function on a molecular level, we measured prostaglandin
levels in cold-acclimated BAT and detected no differences.
Because L-PGDS is a bifunctional molecule capable of
acting both as a carrier of lipophilic molecules (46) and as
a prostaglandin synthase (15), the absence of changes in
prostaglandins suggested that L-PGDS may act primarily as
a lipocalin in terms of its regulatory role in BAT. What
L-PGDS binds to and how that molecule may regulate BAT
function will be an area for future study.
In summary, L-PGDS appears to regulate the balance
between carbohydrate and lipid metabolism in BAT.
The association between metabolic health and an ability
to switch between carbohydrate and lipid metabolism is
already established; however, the ability of L-PGDS to
control the balance between lipid and carbohydrate utili-
zation, with only minor effects on metabolic rate, highlights
a new type of control mechanism for whole organism
substrate handling that could potentially be used to bypass
states of nutritionally induced or genetic insulin resistance.
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